OliX Pharmaceuticals Inc. announced that the company has selected Pharmaron to conduct non-clinical toxicity studies to evaluate the safety of OLX703A, OliX?s investigational therapeutic for hepatitis B (HBV). OLX703A utilizes GalNAc-asiRNA technology and is designed to inhibit all HBV transcripts and proteins, including hepatitis B surface antigen (HBsAg). It allows suppression of HBV replication and has been confirmed to be functional against all major HBV genotypes and subtypes.